This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Aug 14;376(9740):489-90.

doi: 10.1016/S0140-6736(10)61080-X.

Rimonabant: obituary for a wonder drug

S Matthijs Boekholdt¹, Ron J G Peters

Affiliations

PMID: 20709215
DOI: 10.1016/S0140-6736(10)61080-X

Comment

Rimonabant: obituary for a wonder drug

S Matthijs Boekholdt et al. Lancet. 2010.

. 2010 Aug 14;376(9740):489-90.

doi: 10.1016/S0140-6736(10)61080-X.

Authors

S Matthijs Boekholdt¹, Ron J G Peters

Affiliation

¹ Department of Cardiology, Academic Medical Center, 1100DD Amsterdam, Netherlands. s.m.boekholdt@amc.uva.nl

PMID: 20709215
DOI: 10.1016/S0140-6736(10)61080-X

No abstract available

PubMed Disclaimer

Comment on

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Topol EJ, et al. Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X. Lancet. 2010. PMID: 20709233 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information